This policy does not designate specific special histochemical stains (aka
special stains) and/or immunohistochemical (IHC) stains that should be used in
the differential diagnosis of tissues or neoplasms because this information is
readily available in textbooks and various scientific publications. This
policy identifies the medically necessary criteria for the use of special
stains and/or IHC stains and addresses, based on claims review, the scenarios
that may be driving medically unnecessary over-utilization or incorrect
billing of these services including:

  * Reflex templates or pre-orders for special stains and/or IHC stains prior to review of the routine hematoxylin and eosin (H&E) stain by the pathologist; or
  * Use of special stains and/or IHC stains without clinical evidence that the stain is actionable or provides the treating physician with information that changes patient management, or
  * Use of added stains when the diagnosis is already known based on morphologic evaluation of the primary stain.

**Background**  
  
Routine hematoxylin and eosin (H&E) staining is the corner stone of tissue-
based microscopic diagnosis. Thin sections of tissue are stained with H&E to
visualize the tissue morphology. Hematoxylin dye stains the cell nuclei blue
and the eosin dye stains other structures pink/red. H&E staining provides
excellent detail required for tissue-based diagnosis and is NOT a separate
service, as pathology services includes routine H&E staining.  "Acid
hematoxylin" is not as a special stain given that all hemotoxylin stains are
acidic and that this stain has never been recognized by the Biological Stain
Commission. It is not reasonable and necessary to claim this  stain as a
special stain. H&E staining is included as part of pathology services.  
  
Special stains are called "special" because they are dyes used to stain
particular tissues, structures or pathogens such as bacteria that may not be
visible by routine H&E staining. Special stains can identify whether a
substance is present or absent, where the substance is located in the tissue
specimen, and frequently, how many or how much of a substance is present.
There are special stains to identify bacteria, yeast and fungi; for connective
tissue, muscle, collagen, lipid and fibrin; for nuclei acids; and multi-
purpose stains to identify basement membranes, mucins, and various other
cellular constituents. Two major categories for special stains are recognized:
One is specifically for microorganisms; the second code is for all other
purposes (not microorganisms) and specifically excludes detection of enzyme
constituents.  
  
IHC is a powerful tool for identifying substances and cells in tissue sections
using the specificity of antigen-antibody reactions, where the antibody is
linked to a colored indicator (stain) that can be seen with a microscope. More
than 400 distinct antibody targets are currently available with varying
sensitivity and specificity for a given target. A major use of IHC is to
identify poorly differentiated malignant neoplasms (tumors) such as a
carcinoma, lymphoma, melanoma and sarcoma. Some IHC stains are useful in
determining the primary site of a metastatic neoplasm, and others are used to
guide specific therapies (e.g., Her2 IHC to determine potential response to
trastuzumab).  
  
 **Medical Necessity of Services Performed**  
  
There are many different relationships that exist in the provision of
pathology services in the United States. Some physicians, groups, laboratories
and hospitals submit global claims for the services described in this policy.
In other instances, there are separate individuals or entities providing the
professional and technical services. It is the obligation of each party to
recognize that they are responsible for the medical necessity of the services
submitted. For example, when a physician or physician group performs the
professional component of services described in this policy and another entity
performs the technical services, it is the obligation of each entity to
independently assure the medical necessity of the services rendered by each
entity.  
  
 **Special Stains/IHC Medical Necessity**  
  
The CMS Internet-Only Manual, Pub. 100-02, Medicare Benefit Policy Manual,
Chapter 15, 80.6.5 specifies "...there may be additional tests, such as special
stains, that the pathologist may need to perform, even though they have not
been specifically requested by the treating physician/practitioner. The
pathologist may perform such additional tests under the following
circumstances:

  * Services are  **medically necessary**  so that a complete and accurate diagnosis can be reported to the treating physician/practitioner;
  * **Results**  of the tests are communicated to and are used by the treating physician/practitioner in the treatment of the beneficiary; and
  * Pathologist  **documents**  in his/her report  **why**  additional testing was done."

  
The above citation means that reflex templates or pre-orders for special
stains and/or IHC stains prior to review of the routine H&E stain by the
pathologist are not reasonable and necessary. A pathologist must first review
the H&E stain prior to ordering special stains or IHC.  
  
Exceptions do exist and are recognized standards of care in the practice of
pathology. These exceptions include but are not limited to renal, liver, and
neuromuscular biopsies, and for the suspicion of an infectious disease,
particularly in an immune compromised patient. In certain clearly defined
circumstances, it may be reasonable to perform some IHC on sentinel lymph
nodes when the frozen sections show they are free of tumor.  
  
The medical necessity for the special stain or IHC studies, and the results of
the stain or IHC, must be documented in the surgical pathology report.  
  
 **IHC for Breast Pathology**  
  
The clinical care of patients with breast cancer depends upon the accurate
diagnosis and the assessment of biomarkers. Hormone receptor assays and Her2
testing are recommended on all primary  **invasive**  breast cancers, and on
recurrent or metastatic cancers. At the current time, there is no
recommendation for Her2 testing on in situ breast lesions outside of a
clinical trial. While there are a number of promising additional biomarkers,
such as Ki-67, PI3K and gene expression assays, the College of American
Pathologists (CAP), the American Society of Clinical Oncologists (ASCO) and
the National Comprehensive Cancer Network (NCCN) have not recognized these
markers in patient treatment pathways.  
  
Estrogen receptor (ER), progesterone receptor (PR) and epidermal growth factor
receptor 2 (Her2) are well-established prognostic markers in invasive breast
cancer management. The triple negative breast carcinoma subtype
(ER-/PR-/Her2-) has been associated with worse overall prognosis in comparison
with other subtypes in study populations consisting of ethnic minorities and
young women.  
  
Ki-67 expression is a biomarker for proliferation and has been associated with
response to therapy, but methods of measurement are controversial. In
December, 2013, the CAP reported that there is "a lack of consensus on
scoring, definition of low versus high expression, an appropriate cut point
for positivity, or which part of the tumor should be scored (e.g., leading
edge, hot spots, overall average). There is also paucity of data on the
effects of pre-analytical variables (e.g., ischemic time, length of fixation,
antigen retrieval) on Ki-67 staining. For these reasons, routine testing of
breast cancers for Ki-67 expression is not currently recommended by either
ASCO or the NCCN." Consequently, Ki-67 is not reasonable and necessary for
breast cancer and will not be covered by Medicare.  
  
The clinical utility of testing for hormone receptors in in-situ breast cancer
differs from those of invasive disease. Guidelines and the peer reviewed
literature support the use of ER testing for in-situ breast neoplasia and PR
testing only when the ER status is negative (Lester, personal communication).
Clinical guidelines have not been established for the use of Her2 or other
biomarkers in patients with non-invasive breast neoplasia.  
  
In the absence of professional guidelines based on proven scientific
literature, standing orders from clinicians for such tests as Ki-67 and EGFR
on every breast cancer are not reasonable and necessary, and are not a covered
Medicine service.  
  
In addition, basal phenotype markers (eg, IHC for CK5) are not routinely
necessary. Neither are IHC stains such as E-cadherin, p27, or high molecular
weight cytokeratin to distinguish ductal from lobular differentiation
necessary on every breast case, nor are myoepithelial cell markers such as p63
or smooth muscle myosin heavy chain necessary on every case.  
  
 **Special Stains and/or IHC for Gastrointestinal (GI) Pathology**  
  
Pathologists are often called upon to microscopically diagnose abnormalities
seen on endoscopic exam of the esophagus, stomach, duodenum and colon. Biopsy
specimens constitute an important diagnostic patient service. Most normal and
abnormal conditions of these organs can be detected by the use of the routine
H&E stain alone.  
  
Only the pathologist may determine the medical necessity of a special stain.
Ordering special stains or IHC stains prior to review of the routine H&E stain
is not reasonable and necessary. For most esophageal, gastric and duodenal
specimens, it is not reasonable or necessary to perform special stains such as
alcian blue - periodic acid Schiff (AB-PAS), or other mucin stains, such as
diastase - PAS (D-PAS), or IHC stains such CDX-2 to determine if clinically
meaningful intestinal metaplasia is present. In addition, it is not usually
reasonable and necessary to perform special stains or IHC to determine the
presence of H. pylori organisms.  
  
Other examples of special stains or IHC that are not reasonable and necessary
on every specimen include:  
  

  * Esophagus - fungal stains, trichrome, D-PAS, CDX-2 or other mucin stains
  * Gastric - AB-PAS, D-PAS, CDX-2 or other mucin stains, or special stains or IHC for H. pylori, or neuroendocrine markers such as synaptophysin or chromogranin
  * Duodenum - AB-PAS, D-PAS, CD3, and trichrome, or other mucin stains
  * Colon - CD3, p53 trichrome
  * Hyperplastic polyps - Ki67, CK20, p53, CEA, BRAF
  * Tubular or tubulovillous adenoma - Ki-67, CK20, CEA, p53, MMR

If special stains or IHC are needed in addition to the routine H&E for gastric
specimens, specific documentation to justify the medical necessity for the
stain is required in the pathology report. Cases that may require special
stains or IHC include but are not limited to the following:

  * Detection of H pylori in an appropriate milieu when organisms are not seen on H&E stained slides;
  * Evaluating atrophic gastritis for evidence of autoimmune etiology and for enterochromaffin-like (ECL) cell hyperplasia/carcinoid tumor
  * Characterizing a carcinoma, lymphoma, melanoma or sarcoma
  * Defining a GIST tumor and to distinguish it from mimics
  * Ki-67 by IHC in the differential diagnosis of certain neuroendocrine tumors of the gut

Scientific data demonstrates that the combined number of gastric biopsies
requiring special stains or IHC is roughly 20% of biopsies received and
examined in a pathology practice. GI specialty practices with a large GI
referral base or GI consultant pathologists may sometimes exceed this relative
number of special stains/IHC, but one would not expect to see routine high
utilization of special stains or IHC. To check utilization, we encourage
providers to perform a self-audit on the number of separate gastric biopsies
as compared to ancillary stains. The ancillary stain group should be less than
20% of the total gastric biopsies submitted. Providers that exceed the 20%
criteria may be subject to additional action.  
  
Over-utilization of special stains has also been observed with duodenal
biopsies where CD3 and AB/D-PAS are reportedly used to help exclude
intraepithelial lymphocytosis and gastric metaplasia. Both of these
conditions, if present, are easily recognizable on H&E morphology. Mucin
stains such as AB-PAS or DPAS would be reasonable and necessary in limited
circumstances, and rarely is CD3 warranted on duodenal biopsies which show
villous architectural abnormalities.  
  
Architectural and histologic features define colonic polyps including
hyperplastic, inflammatory, and adenomatous lesions. Special stains and/or IHC
stains are not reasonable and necessary for colon polyps despite textbooks
noting, for example, thickened subepithelial collagen demonstrated by
trichrome or collagen staining in hyperplastic polyps, or carcinoembryonic
antigen (CEA) overexpression in hyperplastic polyps. While the information is
of academic interest, special stains are not reasonable and necessary to make
the diagnosis of various colonic polyps.  
  
Lynch Syndrome (LS) tumor screening for DNA mismatch repair (MLH1, MSH2, MSH6
and PMS2) by qualitative IHC and/or microsatellite instability (MSI) is
considered medically necessary and covered by Medicare for the following
indications:

  * All individuals with colorectal cancer diagnosed at age 70 years of age, and those > 70 years of age who meet the revised Bethesda guidelines  **OR**
  * Individuals with endometrial cancer

No definitive algorithm for LS screening has been recommended. However, if IHC
is done first and is abnormal, MSI testing is not warranted. If IHC is normal,
MSI may be warranted. IHC testing LS is qualitative and does not require the
use of tumor morphometry.  
  
 **Special Stains and/or IHC for Prostate Pathology**  
  
The accuracy of the pathologic diagnosis of prostate cancer is critical for
optimal patient care. The diagnosis can usually be made on morphologic
features such as growth pattern, nuclear atypia and the absence of basal
cells. However, it may be difficult to reach a firm diagnosis by routine H&E
stain for small foci of cancer in needle biopsies because many benign
conditions can mimic prostate cancer.  
  
The immunohistochemical diagnosis of prostate cancer largely depends on panels
of markers because no absolutely specific and sensitive marker for prostate
cancer has yet been identified. These panels usually include at least 1 basal
cell marker, such as high-molecular-weight cytokeratin (HMWCK) or p63, and the
prostate cancer-specific marker, alpha-methyl-CoA-Racemase (AMACR). Although
AMACR is considered a useful IHC marker for prostate cancer, because of non-
standardized immunostaining protocols, interpretation criteria and
heterogeneous staining pattern, there is wide variation in the sensitivity and
specificity of AMACR immunoreactivity in prostate biopsies. Furthermore,
because AMACR expression has been demonstrated in high-grade prostatic
intraepithelial neoplasia (PIN), atypical adenomatous hyperplasia/adenosis and
nephrogenic adenoma, it is recommended that AMACR is best restricted to the
evaluation of morphologically highly suspicious foci in which negative
immunoreactivity of basal cell markers alone is insufficient to establish a
diagnosis of cancer.  
  
PTEN and MYC may provide some prognostic information but neither is part of
any standard treatment protocol and neither should be routinely performed. ERG
is another IHC that is more likely to be positive in cancer than in benign
tissue, but it does not add information to conventional PIN4 testing.
Similarly, neuroendocrine markers, such as IHC for synaptophysin, may be
indicated in cases of recurrent/metastatic prostate carcinoma that have
undergone small cell transformation after hormone therapy. The latter marker
is only necessary for high grade, undifferentiated tumors and should not be
used routinely.  
  
PIN4 is an IHC cocktail of CK5/14, p63 and P504S that is used primarily to
differentiate normal and neoplastic epithelial tissues. In prostate tissue,
CK5 and CK14 are detected in basal cells of normal glands and PIN which is a
precursor lesion to prostatic adenocarcinoma. However, expression of CK5 and
CK14 is not identified in invasive prostatic adenocarcinoma. P63 is detected
in nuclei of basal epithelium in normal prostate glands, but is not expressed
in malignant prostate tumors. Because P504S (aka AMACR) is not specific for
prostatic adenocarcinoma, the use of PIN4 is best restricted to evaluation of
morphologically highly suspicious foci.  
  
It is not reasonable and necessary to perform IHC testing (either single
antibody or antibody cocktails) on cases with morphologically negative cores.
It is not reasonable and necessary to perform for IHC testing in a negative or
a suspicious core biopsy when obvious prostate cancer is present in other
cores. While the pathologist may choose to confirm a suspicious focus in one
or more cores in a case where the diagnosis of cancer has already been made,
it is not a Medicare covered service because it provides no additional
actionable information to the treating physician.  
  
Prostate cases that may require reasonable and necessary IHC staining include
but are not limited to the following:

  * Indeterminate/suspicious focus and no other cores are positive for cancer
  * Single worrisome core with minimal % tumor (roughly <5%)
  * Worrisome core(s) contralateral to a positive core(s):
    * In a multi-part biopsy with Gleason 3+3=6 cancer in 1 part, and atypical small acinar proliferation (ASAP) suspicious for Gleason 3+3=6 cancer in other part(s); the number of positive biopsy sites and % core involvement of these sites can affect therapeutic choices for active surveillance (AS), focal therapy or surgery
    * In a multi-part biopsy with 4+3=7 or 4+4=8 cancer in 1 part, and ASAP suspicious for the same grade cancer in other part(s); workup is justified since the extent of high-grade cancer affects treatments
  * Identify tumor invasion of adjacent structures
  * Determine origin of undifferentiated/poorly differentiated neoplasm, such as bladder vs. prostate
  * Other unexpected results when specific cell stains would be necessary

Prostate cases when IHC workup is  **Not Reasonable and Necessary**  include
the following:

  * In a multi-part biopsy with 3+4=7 cancer in 1 part, and ASAP suspicious for 3+3=6 cancer in other part(s), because stains are unlikely to change treatment; or
  * In a multi-part biopsy with 4+3=7 cancer in 1 part, and "atypical cribriform lesson" (ACL) suspicious for intra-ductal carcinoma versus invasive, Gleason pattern 4 cancer in other part(s), because intra-ductal carcinoma is almost always closely associated with invasive high-grade cancer.

The International Society of Pathology (ISUP) recommendations state that at
the current time, there are no prognostic IHC or molecular studies that are
recommended to be routinely performed on biopsy or resection specimens.  
  
The surgical pathology report is expected to designate the specific block(s)
upon which IHC testing is performed, the reason for IHC testing, the specific
markers, and whether single antibody(ies) or a cocktail of antibodies is
utilized. A statement alone in the pathology report that states "IHC confirms
the diagnosis" will not be covered as reasonable and necessary.  
  
 **Special Stains and/or IHC for Lung Cancer**  
  
The diagnostic challenge of a lung biopsy can often prompt the need for
additional stains to define the neoplasm. Two important considerations need to
be considered in this regard:

  * The diagnosis of squamous cell cancer can often be made without the use of any special stains, and
  * The diagnosis of non-small cell carcinoma often requires additional stains but it is essential that tumor tissue be carefully triaged to allow the patient's sample to be tested for molecular markers (EGFR, ALK, and others) when clinically indicated.

Experts in pulmonary pathology recommend starting the evaluation of non-small
cell carcinomas with a combination of TTF-1 and p40 or p63 IHCs. Often these 2
stains are all that are needed to come to a reasonable diagnosis and retain
enough tumor sample to complete molecular studies. In rare patients, a few
additional IHCs or mucin stains may be needed.  
  
 **Ki-67/MIB-1**  
  
Ki-67 and MIB-1 monoclonal antibodies are directed against different epitopes
of the same proliferation-related antigen. These stains are used to determine
the proliferative rate of a tumor. Ki-67 antigen or protein (hereafter Ki-67)
is present during all active phases of the cell cycle (G1, S, G2, and
mitosis), but is absent from resting cells (G0). By measuring the amount of
tumor cells expressing Ki-67, an estimate of DNA synthesis can be determined
which has been found comparable to a mitotic count performed on a standard H&E
slide. Furthermore, Ki-67/MIB-1 antibodies have suffered from a lack of
international standardization which has limited their clinical usefulness.
This is noted above in the discussion of breast cancers.  
  
Classification of lung neuroendocrine (NE) tumors is a step-wise process with
4 tumor categories being identified by morphology, namely:

  * Typical carcinoid (TC),
  * Atypical carcinoid (AC),
  * Large cell NE carcinoma, and
  * Small cell lung carcinoma (SCLC).

Ki-67 has potential usefulness in a narrow range of pathologic lung cases.
Namely, it allows better classification of atypical and typical lung carcinoid
tumors, and in pulmonary neuroendocrine tumors with extensive crush artifact.
(As noted above, Ki-67 may be useful in the classification of some gut
neuroendocrine tumors.)  
  
Ki-67 by IHC has clinical utility in the workup of lymphomas. Ki-67 has
several established applications including:

  * Final confirmation for the diagnosis of any low-grade lymphoma. A number of publications show a worse prognosis for follicular lymphomas which appear to be grade 1 or 2 but demonstrate high Ki-67 labeling. Similarly, small lymphocytic lymphomas/CLL with a high proliferative rate ("prolymphocytic progression") may be best detected with Ki-67.
  * Distinguishing higher versus lower grade mantle cell lymphoma. A small percentage of cases behave as low grade rather than intermediate grade, and Ki-67 is the most accurate means to detect this subgroup. In addition, distinguishing the highly aggressive blastoid variant is aided by Ki-67 IHC testing.
  * Recognizing Burkitt and Burkitt-like grouping as distinct from diffuse large B-cell type. One of the most important qualifying criteria is Ki-67 labeling at greater than 90%.
  * Plasma cell myeloma proliferative rate has long been established as one of the most accurate prognostic markers.

**IHC for Chemosensitivity and Resistance Tumor Profiling**  
  
ER, PR, and Her2 hormonal receptor status have demonstrated clinical utility
in invasive breast cancer, as well as ER, and PR when appropriate, for in-situ
breast cancer. ER and PR are performed by IHC specifically for tamoxifen
therapy. Her2 testing has proven clinical utility in esophago-gastric and
gastric cancers to determine response to trastuzumab. ER, PR and Her2 testing
for the purpose of identifying patients likely to respond to hormonal therapy,
biologics or chemotherapy is a covered Medicare service when medically
necessary for breast and gastric adenocarcinoma.  
  
Similarly, the efficacy of imatinib, a CD117 inhibitor, is determined by the
mutation status of CD117 expression (c-KIT mutation). CD117 by IHC has a
proven clinical benefit in gastrointestinal stromal tumors (GIST), some
advanced dermatofibrosarcoma protuberans (DFSP), some lymphoblastic and
myeloid leukemias, and mast cell tumors, and is a covered Medicare service
when medically necessary.  
  
However, IHC testing as above is distinctly different from chemotherapy
sensitivity and/or resistance testing profiles offered by some labs to assist
physicians in their selection of specific chemotherapeutic agents based on IHC
antigen or protein expression in individual tumors. The goal stated by these
profiles is to select a drug or combination of drugs from a panel of drugs to
which a tumor has greater expression, and to avoid drugs to which the tumor
has less expression.  
  
Neither the ASCO nor the NCCN has endorsed chemosensitivity tumor profile
testing by IHC. ASCO has stated, "the use of CSRA's (chemosensitivity and
resistance assays) to select chemotherapeutic agents for individual patients
is not recommended outside of the clinical trial setting." While the NCCN's
Guidelines for Ovarian Cancer (V3.2014) states "chemosensitivity/resistance
and/or other biomarker assays are being used in some NCCN member institutions
for decisions related to future chemotherapy in situations where there are
multiple equivalent chemotherapy options available. The current level of
evidence is not sufficient (Category 3) to supplant standard of care
chemotherapy." The NCCN panel also stated that in vitro chemosensitivity
testing is choose a chemotherapy regimen for recurrent disease should not be
recommended due to lack of demonstrated efficacy. Such IHC panels include but
are not limited to the following biomarkers for specific drugs:

  * ALK for crixotinib, penetrexed
  * Androgen receptor (AR) for goserelin, leuprolide, gonadorelin, flutamide, bicalutamide, abiraterone;
  * Androgen receptor for bicalutamide, flutamide, abiraterone and enzalutamide;
  * AREG for cetuximab, panitumumab
  * BRAF for venurafenib and dabrafenib
  * BRCA1 for cisplatin, carboplatin
  * cKIT for sorafenib, sunitinib, imatinib
  * cMET for erlotinib, gefitinib
  * EGFR for gefitinib, panitumumab, erlotinib, cetuximab, FOLFIRIEGFRVIII
  * EGFRvIII, GNA11, GNAQ, IDH2 - for clinical trials
  * ER and PR for tamoxifen, gefitinib, toremifene, fulvestrant, letrozole, anastrozole, exemestrane, megestrol acetate, erlotinib, panitumumab, medroxyprogesterone;
  * ERCC1 for oxaliplatin, cisplatin, carboplatin, CAPOX, FOLFOX
  * EREG for cetuximab, panitumumab
  * Her2 (ErbB2), PGP and TOP2A (topoisomerase IIA) for doxorubincin, liposomal-doxorubicin, epirubicin;
  * Her2 or labatinib; epirubicin, pertuzumab, trastuzumab, liposomal doxorubicin, doxorubicin,
  * KRAS for panitumumab, cetruximab, gefitinib, erlotinib, sorafenib
  * MGMT for temozolomide and dacarbazine
  * MRP1 for vinorelbine, vincrisxtine, doxorfubicin, epirubicin, vinblastine, methotrexate
  * NRAS for cetuximab, panitumumab
  * PDGFRA for imatinib
  * PGP (aka MDR1 and ABCB1) for doxorubicin, vincristine, vinblastine, eptoposide, liposomal doxorubicin, paclitaxel , docetaxel, vinorelbine, epirubicin;
  * PIK3CA for lapatinib, panitumumab, trastuzumab, cetuximab, temsirolimus
  * PTEN for getitinib, cetuximab, erlotinib, trastuszumab, panitumumab, everolimus, temsirolimus
  * RET for vandetanib
  * ROS1 for crizotinib
  * RRM1 for gemcitabine;
  * SPARC (monoclonal and polyclonal) for nab-paclitaxel;
  * TLE3, TUBB3 for docetaxel, paclitaxel;
  * TOPO1 for irinotecan, topotecan, FOLFIRI;
  * TS (thymidylate synthase or TYMS) for fluorouracil, capecitabine and pemetrexed

Chemosensitivity profile tumor panels, regardless of whether it is performed
by IHC or chromogenic in-situ hybridization (CISH), is not reasonable and
necessary for the reasons cited above, and is not a Medicare covered service.  
  
Note, some of these markers are legitimate biomarkers for specified drugs when
performed by mutation analysis or FISH testing.  
  
 **IHC for Cervical/Gyn/Bladder/Kidney Tumors**  
  
A variety of IHC stains have found limited use in cervical, gynecologic, and
urologic tumor settings. In unusual cases of cervical dysplasia, markers or
surrogate markers for HPV may be useful where the diagnosis on conventional
H&E stain cannot be made with certainty. These markers are clearly not
reasonable and necessary on all biopsies. Claims data indicate combinations of
gram stain, PAS, Ki-67, p16 and ProExC stains on all cervical biopsies from
select pathology practices, and combinations of p53, Ki-67, CD20 and CD44 on
bladder biopsies from select pathology practices.  
  
Similarly, it is rare to need stains to prove that an endometrial or ovarian
cancer is a serous cancer or that a kidney neoplasm is an oncocytoma or an
eosinophilic or chromophobic renal cell cancer. The use of IHC stains in these
circumstances requires adequate documentation in the pathology report, such as
"Because the differential histologic diagnosis is between an endometrioid
carcinoma and a serous carcinoma, I performed an xxx stain. The controls
worked appropriately and the results were positive indicating the tumor is a
yyy."  
  
 **IHC for Skin & Cutaneous/Soft Tissue/Central Nervous System (CNS) &
Peripheral Nervous System (PNS) Lesions**  
  
It is well recognized that most skin lesions are diagnosed with routine H&E
slides. That is the case for most melanomas and other pigmented lesions as
well. A minority of skin lesions require immunostains (e.g., atypical
fibroxanthomas, Merkel cell lesions, lymphomas). Most common skin lesions
(e.g., seborrheic keratosis) do not require IHC stains. Use of IHC
morphometric codes for skin lesions is not reasonable and necessary.  
  
Similarly, most soft tissue lesions do not require IHC stains or other
"special" stains. Soft tissue masses may require stains (e.g., smooth muscle
differentiation in a malignant mass) but the most do not.  
  
Many CNS and peripheral nervous system lesions are readily diagnosed with
routine stains. It is unusual for a meningioma to require an IHC. The primary
role of IHC for CNS and PNS lesions is to differentiate primary from
metastatic lesions.  
  
 **IHC for Bone Marrow Samples**  
  
Most bone marrow samples are diagnosed with the use of Wright's stained smears
and the use of H&E stained slides with an iron stain supplementing the
battery. The use of IHC stains may assist in the interpretation of cases where
flow cytometry (FC) does not fit with the routine slide interpretation, when
FC was not obtained or for the evaluation of cell types that are not detected
or significantly underrepresented in FC studies, such as large lymphocytes,
plasma cells and Reed-Sternberg cells. IHC stains are generally not needed to
confirm the results of FC and cytogenetic studies. When medically indicated,
justification for the use of both methods must be stated in the pathology
report and billed accordingly.  
  



NA

NA